Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
2020; American Association for Cancer Research; Volume: 26; Issue: 8 Linguagem: Inglês
10.1158/1078-0432.ccr-19-2884
ISSN1557-3265
AutoresAaron T. Scott, Michelle Weitz, Patrick Breheny, Po Hien Ear, Benjamin W. Darbro, Bart J. Brown, Terry A. Braun, Guiying Li, Shaikamjad Umesalma, Courtney A. Kaemmer, Chandra K. Maharjan, Dawn E. Quelle, Andrew M. Bellizzi, Chandrikha Chandrasekharan, Joseph S. Dillon, Thomas M. O’Dorisio, James R. Howe,
Tópico(s)Lung Cancer Research Studies
ResumoPancreatic neuroendocrine tumors (pNETs) are uncommon malignancies noted for their propensity to metastasize and comparatively favorable prognosis. Although both the treatment options and clinical outcomes have improved in the past decades, most patients will die of metastatic disease. New systemic therapies are needed.
Referência(s)